Skip to Content

'
Robert S. Bresalier, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Gastroenterology, Hepatology & Nutrition, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1400 Pressler
Unit Number: Unit 1466
Houston, TX 77030-4009
Phone: 713-745-4340
Fax: 713-745-9295

Education & Training

Degree-Granting Education

1978 University of Chicago, Chicago, IL, MD, Medicine
1973 State University of New York at Stonybrook, Stonybrook, NY, BS, (Honors), Biological Sciences

Postgraduate Training

7/1981-6/1984 Fellowship, Gastroenterology, University of California, San Francisco, San Francisco, CA
7/1978-6/1981 Residency, Internal Medicine, Barnes Hospital, Washington University, St. Louis, MO

Board Certifications

1983 American Board of Internal Medicine, Gastroenterology
1981 American Board of Internal Medicine, Internal Medicine

Experience/Service

Endowed Positions

Birdie J. and Lydia J. Resoft Distinguished Professor in Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2003-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Barry EL, Poole EM, Baron JA, Makar KW, Mott LA, Sandler RS, Ahnen DJ, Bresalier RS, McKeown-Eyssen GE, Ulrich CM. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. Cancer Causes Control. e-Pub 10/19/2012. PMID: 23081681.
2. Sung JJ, Ng EK, Lin Jt, Ho KY, Ji JR, Sugano K, Poon RT, Chan AT, Goh KL, Han KH, Chen LL, Wu KC Ng SS, Bresalier RS, Chan FK. Digestive cancer management in Asia: Position statements: A report on GI Oncology Summit in 2011. J Gastroenterol Hepatol 27(9):1417-1422, 9/2012. PMID: 22694174.
3. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Sanderson AK, Bresalier R, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD. Factors Associated with Inadequate Colorectal Cancer Screening with Flexible Sigmoidoscopy. Cancer Epidemiol 36(4):395-9, 8/2012. e-Pub 11/22/2011. PMCID: PMC3288883.
4. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD, PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366(25):2345-57, 6/21/2012. e-Pub 5/21/2012. PMID: 22612596.
5. Yurgelun MB, Goel A, Hornick JL, Sen A, Turgeon DK, Ruffin MT, Marcon NE, Baron JA, Bresalier RS, Syngal S, Brenner DE, Boland CR, Stoffel EM. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) 5(4):574-82, 4/2012. e-Pub 1/18/2012. PMID: 22262812.
6. Mazurek N, Byrd JC, Sun Y, Hafley M, Ramirez K, Burks J, Bresalier RS. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ 19(3):523-33, 3/2012. e-Pub 9/23/2011. PMCID: PMC3246527.
7. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier RS, Hickey T, Riley T, Prorok PC. Colorectal Cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Gastrointestinal Endoscopy 75(3):612-20, 3/2012. PMID: 22341106.
8. Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Doria-Rose VP, Laiyemo AO, Church T, Yokochi LA, Yurgalevitch S, Rathmell J, Andriole GL, Buys S, Crawford ED, Fouad M, Isaacs C, Lamerato L, Reding D, Prorok PC, Berg CD, PLCO Project Team. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst 104(4):280-9, 2/22/2012. e-Pub 1/31/2012. PMCID: PMC3283538.
9. Song S, Ji B, Ramachandran V, Wang H, Hafley M, Logsdon C, Bresalier RS. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding ras and activating ras signaling. PLoS One 7(8):e42699, 2012. e-Pub 8/10/2012. PMCID: PMC3416861.
10. Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer 117(19):4375-80, 10/2011. e-Pub 3/2011. PMCID: PMC3164935.
11. White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretices: a pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens (Greenwich) 13(7):506-16, 7/2011. PMID: 21762364.
12. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team. Effect of screening on ovairan cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22):2295-303, 6/2011. PMID: 21642681.
13. Tong Z, Chakraborty S, Sung B, Koolwal P, Kaur S, Aggarwal BB, Mani SA, Bresalier RS, Batra SK, Guha S. Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. Cancer 117. e-Pub 12/29/2010. PMCID: PMC3134548.
14. Song S, Byrd JC, Guha S, Liu KF, Koul D, Bresalier RS. Induction of MUC5AC mucin by conjugated bile acids in the esophagus involves the phosphatidylinositol 3-kinase/protein kinase C/activator protein-1 pathway. Cancer. e-Pub 12/14/2010. PMCID: PMC3116027.
15. Bresalier RS. Management of high-risk colonoscopy patients. Gastrointest Endosc Clin N Am 20(4):629-40, 10/2010. PMID: 20889068.
16. White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich) 12(10):765-75, 10/2010. PMCID: PMC3057428.
17. Wong HL, Peters U, Hayes RB, Huang WY, Schatzkin A, Bresalier RS, Velie EM, Brody LC. Polymorphisms in the adenomatous polyposis coli (APC) gene and advanced colorectal adenoma risk. Eur J Cancer 46(13):2457-66, 9/2010. e-Pub 5/24/2010. PMCID: PMC2924917.
18. Shafi MA, Bresalier RS. The gastrointestinal complications of oncologic therapy. Gastroenterol Clin North Am 39(3):629-47, 9/2010. PMID: 20951921.
19. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, Crawford ED, Kvale P, Fouad M, Hickey T, Riley T, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst 102(8):538-46, 4/21/2010. e-Pub 3/31/2010. PMCID: PMC2857802.
20. Weston BR, Iyer RB, Qiao W, Lee JH, Bresalier RS, Ross WA. Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer 116(6):1454-61, 3/15/2010. PMID: 20143447.
21. Waye JD, Heigh RI, Fleischer DE, Leighton JA, Gurudu S, Aldrich LB, Li J, Ramrakhiani S, Edmundowicz SA, Early DS, Jonnalagadda S, Bresalier RS, Kessler WR, Rex DK. A retrograde-viewing device improves detection of adenomas in the colon: a prospective efficacy evaluation (with videos). Gastrointest Endosc 71(3):551-6, 3/2010. e-Pub 12/16/2009. PMID: 20018280.
22. Ruffin MT, Normolle DP, Evelegh MJ, Baron JA, Bresalier RS, Marcon NE, Syngal S, Turgeon DK, Tuck MK, Brenner DE. Rectal mucosal quantitative galactose oxidase-Schiff reaction as an early detection biomarker for colorectal cancer: comparison to fecal occult stool blood test. Cancer Biomark 8(2):109-12, 2011, 2010. PMID: 21896998.
23. Ho GY, Xue X, Cushman M, McKeown-Eyssen G, Sandler RS, Ahnen DJ, Barry EL, Saibil F, Bresalier RS, Rohan TE, Baron JA. Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. J Natl Cancer Inst 101(23):1650-4, 12/2/2009. e-Pub 10/12/2009. PMCID: PMC2786916.
24. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 18(10):2726-33, 10/2009. e-Pub 9/15/2009. PMCID: PMC2769932.
25. Robertson DJ, Burke CA, Welch HG, Haile RW, Sandler RS, Greenberg ER, Ahnen DJ, Bresalier RS, Rothstein RI, Cole B, Mott LA, Baron JA. Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. Ann Intern Med 151(2):103-9, 7/21/2009. PMCID: PMC2779048.
26. Bresalier RS. Early detection of and screening for colorectal neoplasia. Gut Liver 3(2):69-80, 6/2009. e-Pub 6/30/2009. PMCID: PMC2852697.
27. Figueiredo JC, Grau MV, Wallace K, Levine AJ, Shen L, Hamdan R, Chen X, Bresalier RS, McKeown-Eyssen G, Haile RW, Baron JA, Issa JP. Global DNA Hypomethylation (LINE-1) in the Normal Colon and Lifestyle Characteristics and Dietary and Genetic Factors. Cancer Epidemiol Biomarkers Prev 18(4):1041-9, 4/2009. e-Pub 3/31/2009. PMID: 19336559.
28. Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, Burke CA, McKeown-Eyssen GE, Baron JA. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 101(6):432-5, 3/18/2009. e-Pub 3/10/2009. PMCID: PMC2657096.
29. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-9, 3/26/2009. e-Pub 3/18/2009. PMID: 19297565.
30. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, Hung MC, Bresalier RS. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 69(4):1343-9, 2/15/2009. e-Pub 2/3/2009. PMID: 19190323.
31. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JA. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst 101(4):267-76, 2/18/2009. e-Pub 2/10/2009. PMCID: PMC2644329.
32. Song S, Krishnan K, Liu K, Bresalier RS. Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression. Clin Cancer Res 15(2):622-31, 1/15/2009. PMID: 19147768.
33. Robertson D, Burke C, Gilbert-Welch H, Haile R, Sandler Robert, Greenberg Robert, Ahnen D, Bresalier R, Rothstein R, Cole B, Mott L, Baron J. Estimated Risk of Advanced and Multiple Adenomas Based On the Results of Two Prior Colonoscopies. Gastroenterology 151:103-09, 2009.
34. Andriole G, Crawford E, Grun R, et. al. Mortality rates from a randomized prostate cancer screening trial. New England Journal of Medicine 360:1310-1319, 2009.
35. Stoffel EM, Turgeon DK, Stockwell DH, Normolle DP, Tuck MK, Marcon NE, Baron JA, Bresalier RS, Arber N, Ruffin MT, Syngal S, Brenner DE, Brenner DE. Chromoendoscopy detects more adenomas than colonoscopy using intensive inspection without dye spraying. Cancer Prev Res (Phila Pa) 1(7):507-13, 12/2008. PMID: 19139000.
36. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton D, Riddell R, Iverson ER, Demets, DL.. Cardiovascular events associated with rofecoxib: Final Analysis of the APPROVe Trial. Lancet 372(9651):1756-64, 11/2008. e-Pub 10/14/2008. PMID: 18922570.
37. Chan FK, Abraham NS, Scheiman JM, Laine L, First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 103(11):2908-18, 11/2008. e-Pub 10/1/2008. PMID: 18853980.
38. Stoffel EM, Turgeon DK, Stockwell DH, Zhao L, Normolle DP, Tuck MK, Bresalier RS, Marcon NE, Baron JA, Ruffin MT, Brenner DE, Syngal S, Syngal S. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila Pa) 1(6):470-5, 11/2008. PMID: 19138994.
39. Davila M, Bresalier RS. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 5(12). e-Pub 10/21/2008. PMID: 18941434.
40. Figueiredo J, Levine J, Grau M, Barry E, Ueland PM, Ahnen D, Byers T, Bresalier R, Syummers R, Bond j, Eyssen G, Sandler R, Haile R, Baron J.. Colorectal Adenomas in a Randomized Folate Trial: The Role of Baseline Dietary and Circulating Folate Levels. Cancer Epidemiol Biomarkers Prev 17(10):2625-31, 10/2008. PMCID: PMC2597215.
41. Bresalier RS. Barrett's esophagus and esophageal adenocarcinoma. Annu Rev Med. e-Pub 9/2008. PMID: 18783330.
42. Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, Jin G, Ruffin MT, Turgeon DK, Synal S, Bresalier R, Marcon N, Brenner DE, Lubman DM. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res 7(4):1693-703, 4/2008. e-Pub 2/27/2008. PMID: 18311904.
43. Bresalier RS. Chemoprevention of colorectal cancer: why all the confusion? Curr Opin Gastroenterol 24(1):48-50, 1/2008. PMID: 18043232.
44. Tong Z, Kunnumakkara AB, Wang h, Matsuo Y, Diagaradjane P, Harikumar KB, Ramachandran V, Sung B, Chakraborty A, Bresalier RS, Logsdon C, Aggarwal BB, Krishnan S, and Guha S.. Neutrophil Gelatinase-Associated Lipocalin: A Novel Suppressor of Invasion and Angiogenesis in Pancreatic Cancer. Cancer Res 68(15):6100-6108, 2008. PMID: 18676832.
45. Dixon LB, Subar AF, Peters U, Weissfeld JL, Bresalier RS, Risch A, Schatzkin A, Hayes RB. Adherence to the USDA Food Guide, DASH Eating Plan, and Mediterranean dietary pattern reduces risk of colorectal adenoma. J Nutr 137(11):2443-50, 11/2007. PMID: 17951483.
46. Mazurek N, Sun YJ, Liu KF, Gilcrease MZ, Schober W, Nangia-Makker P, Raz A, Bresalier RS. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J Biol Chem 282(29):21337-48, 7/20/2007. e-Pub 4/9/2007. PMID: 17420249.
47. Song S, Guha S, Liu K, Buttar NS, Bresalier RS. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 56(11). e-Pub 6/29/2007. PMCID: PMC2095641.
48. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER, Greenberg ER. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297(21):2351-9, 6/6/2007. PMID: 17551129.
49. Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer 109(4):668-74, 2/15/2007. PMID: 17211862.
50. Lanas A, Baron JA, Sandler RS, Horgan K, Bolognese J, Oxenius B, Quan H, Watson D, Cook TJ, Schoen R, Burke C, Loftus S, Niv Y, Ridell R, Morton D, Bresalier R. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 132(2):490-7, 2/2007. e-Pub 11/10/2006. PMID: 17258718.

Invited Articles

1. Bresalier RS. Early Detection and Screening for Colorectal Neoplasia-Making Sense of the Guidelines. Colorectal Cancer Treatment Reports 6(4):177-179, 2010.
2. Bresalier RS. Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story). Curr Opin Gastroenterol 23(1):44-7, 2007. PMID: 17133084.
3. Bresalier RS. Management of Barrett's Esophagus. Cases and Questions. Seminars in Oncology 2 (/suppl 9):2-5, 2005.

Editorials

1. Bresalier R. Gastrointestinal oncology: A critical multi-disciplinary team approach. Gastroenterology, 2010.
2. Bresalier, RS. Endoscopic Oncology: Gastrointestinal endoscopy and cancer management (book review). Gastoenterology 132:2614-2616, 2007.
3. Bresalier, RS. The biology of cancer (book review). Gastroenterology 133:364-365, 2007.

Abstracts

1. Mazurek N, Byrd JC, Bresalier RS. Cell Surface Expessionof the Anti-Apoptotic B-Galactoside-Binding Protein Galectin-3 is Characteristic of the Stem Cell Phenotype in Colorectal Cancer Cells. Gastroenterology, 2012.
2. Schoen RE, Pinsky P, Weissfeld J, Yokochi LA, Church TR, Laiyemo AO, Bresalier RS, Riley TL, Prorok PC, Berg C. Effect of flexible sigmoidoscopy screening on incidence and mortality from colorectal cancer in the PLCO screening trial. Gastroenterology, 2012.
3. Thosani N, Patel P, Raiyani TV, Raju GS, Bresalier RS, Guha S. Seeing behind the folds - Clinical impact of third eye retroscope on adenoma detection during the colonoscopy: A systematic review and Meta-Analysis. Gastroenterology, 2012.
4. Nguyen D, Tuck M, Sen A, Ruffin MT, Baron JA, Bresalier RS, Marcon NE, McConnell D, Stoffel EM, Syngal S, Brenner DE, Turgeon DK. Sensitivity and specificity of fecal immunochemical and guaiac testing for occult blood in archived frozen stool samples. Gastroenterology, 2012.
5. Bresalier RS, Byrd JC, Mazurek N, Brenner D, Syngal S, Marcon N, Turgeon K, Baron JA. A Circulating Ligand for Galectin-3 Elevated in the Serum of Individuals with Colorectal Neoplasia: Results of a New ELISA Using the EDRN Reference Set. Gastroenterology, 2011.
6. Mazurek N, Byrd JC, Sun YJ, Bresalier R. Cell-surface galectin-3 confers resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by impeding trafficking of DR4 death receptors in colon cancer cells. Gastroenterology, 2010.
7. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier RS, et. al. Factors Associated with Inadequate Colorectal Cancer Screening with Flexible Sigmoidoscopy. Gastroenterology, 2010.
8. Shumei Song, Baoan Ji, Vijaya Ramachandran, Nachman Mazurek, Huamin Wang, Craig D. Logsdon, Robert S. Bresalier. Galectin-3 Induces Cell Proliferation and Invasion by Binding K-RAS and Activating RAS Signaling in Pancreatic Cancer Cells, 2010.
9. Song S, Bresalier RS. Galectin-3 Induces Human Pancreatic Stellate Cell Activation and IL-8 Production via NF-kB signaling. Gastroenterology, 2010.
10. Ueno S, San YJ, Song S, Mazurek N, Byrd JC, Irimura T, Bresalier RS. Galectin-3 polymorphisms and response of human breast and colon cancer cells to apoptotic stimuli. American Association for Cancer Research-Japanese Cancer Association Joint Conference, 2010.
11. Mazurek N, Ueno S, Sun YJ, Byrd JC, Bresalier RS. Galectin-3 sequence polymorphisms predict response of colon cancer cells to chemotherapy. Gastroenterology, 2010.
12. Song S, Mazurek N, Liu C, Sun Y, Ding Q, Liu K, Hung MC, Bresalier R. Galectin-3 mediates nuclear B-Catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3B activity. Cancer Research 69(4):4153, 2/2009.
13. Bresalier R, Byrd J, Mazurek N, Normoelle D, Brenner D, Syngal S, Marcon N, Turgeon D, Baron J. A circulating ligand for galectin-3 elevated in the serum of individuals with colorectal neoplasia:Results of a new ELISA using the EDRN reference set. Procedings of the 6th EDRN Scientific Workshop. 2009.
14. Schoen R, Weissfeld j, Laiyamo A, Doria-Rose P, Bresalier R, Clark T, yokochi l, O'Brien, B, Pinsky P. Comparison of 16 years of flexible sigmoidoscopy (FSG) at three versus five years after a negative exam. Gastroenterology, 2009.
15. Mazurek N, Byrd J, Sun Y, Bresalier R. Galectin-3 sequence polymorphisms dictate TRAIL sensativity or resistance of human breast cancer cells. Proceedings of the American Association of Cancer Research. 50:27, 2009.
16. Mazurek N, Byrd J, Bresalier R. Nuclear galectin-3 confers tumor necrosis factor-related apoptosis-inducing ligan (TRAIL) resistance to colon cancer cells by inhibiting caspase-8 activation. Gastroenterology, 2009.
17. Laiyemo A, Doubeni C, Pinsky P, Doria-Rose P and Bresalier R. Race, ethnicity and colorectal disparities: Is there a difference in adenoma indication? Evidence from 16 prostate, lung, colorectal and ovarian (PLCO) cancer screening trials. Gastroenterology, 2009.
18. Waye J, heigh R, Fleischer S, Leighton J, Gurudu S, Aldrich L, Li j, Ramrakiani S, Jonnalagadda S, Bresalier R, Kessler W, Rex D. The third eye retroscope auxillary endoscopy system improves detection of adenomas in the colon: A prospective efficacy study. Gastroenterology, 2009.
19. Waye J, Heigh R, Fleicher D, Leighton J, Aldrich, Li J, Ramrakhiani S, Edmundowicz S, Early D, Bresalier RS, Kessler W, Rex D. A prospective efficacy study of the Third Eye Retroscope Auxiliary Endoscope System. Gastroenterology, 2008.
20. Byrd J, Yan P, Bresalier R. Expression of MAC-2 BP, ligand for galectin-3, in Barrett's esophagus, esophageal adenocarcinoma and squamous cell carcinoma. Proceedings of the XXVII Congress of the International Academy of Pathology, 2008.
21. Song S, Mori-Akayama Y, Liu K, de Crombrugghe B, Bresalier RS. Regulation of SOX-9 and Wnt signaling in human colon cancer cells. Gastroenterology 134:A76, 2008.
22. Song S, Byrd J, Bresalier RS. Differential regulation of COX-2 and cyclin D1 by bile acids at neutral and acid pH in esophageal adenocarcinoma cells. Gastroenterology 132:A417, 2007.
23. Song S, Mazurek N, Liu C, Liu KF, Bresalier RS. Galectin-3 mediates nuclear Beta-catenin accumulation and Wnt signaling in human colon cancer cells through regulation of Gsk-3beta activity. Gastroenterology 132:A129, 2007.
24. Bresalier, RS. Galection targets: the role of galectin-3 in the progression and metastasis of colorectal neoplasia. Proceedings of the American Chemical Society, 2007.
25. Half E, Song S, Sun Y, Bresalier RS. Sulindac and Gefitinib inhibit MUC2 and MUC5AC mucin expression via Akt and Mapk pathways in human colon cancer cells. Gastroenterology 132:A306, 2007.

Book Chapters

1. Byrd JC, Mazure N, Bresalier RS. Post translational modification of galectin-3 and its role in biological function. In: Klyosov AA and Traber PG Galectins and Disease. Implications for targeted therapeutics. John Wiley and Sons, 158-175, 2012.
2. Boland C and Bresalier R. Colonic polyps and polyposis syndromes. In: Surgery Scientific Principles and Practices, Fifth. Ed(s) Greenfield L, Mulholland K, Zeleneck G. Lippncott: Philadelphia, 2011.
3. Davila M and Bresalier R. Gastrointestinal complications of cancer treatment. In: Holland-Frei Cancer Medicine, eighth. Ed(s) Kufe D, Bast R, Hait W, Hong W, Pollack R, Weichselbaum R, Holland J, Frei E. Hamilton: Ontario, 2010.
4. Bresalier R. Malignant Neoplasms of the Large Intestine. In: Gastrointestinal Disease, Ninth. Ed(s) Feldman M, Friedman L, Brandt L. WB Saunders: Philadelphia, 2155-2190, 2010.
5. Byrd JC and Bresalier RS. Galectin-3 in the progression and metastasis of colorectal neoplasia. In: Galectins. 60. John Wiley and Sons, 221-232, 2009.
6. Bresalier RS. Tumors of the Small Intestine. In: Atlas of Gastroenterology, 4th edition. Ed(s) Yamada T, Alpers D, Owyang C, Powel D, (eds). Lippincott: Phil, PA, 1322-1342, 2009.
7. Bresalier RS, Anandasabapathy S. Tumors of the Small Intestine. In: Textbook of Gastroenterology, 5th edition. Ed(s) Yamada T, Alpers D, Owyang C, Powel D, (eds), 358-373, 2009.
8. Bresalier RS. Epidemiology, Genetics and Prevention of Colorectal Cancer. In: Atlas of Cancer Second Edition. Upper and Lower GI Tract Cancers. Second Edition. Ed(s) Ajani J, Hoff P, 2008.

Books (edited and written)

1. Bresalier R, Bhutani M, Eds. Atlas of Gastrointestinal Cancer: A Multidisciplinary Approach to Diagnosis, Staging and Treatment. John Wiley & Sons Ltd: London, 2011. ISBN: 9781405195546.
2. Bresalier RS. Current Opinion in Gastroenterology. In: Large Intestine. 25, No. 1. Lippincott, Williams and Wilkins, 2009.
3. Bresalier RS, Section Editor. Ed(s) Yeung S, Escalante C, Gagel R. Disorders of the Gastrointestinal Tract and Nutrition. In: Internal Medicine Care of Cancer Patients. Series Ed(s) Yeung SJ, Escalante C, Gagel RF. BC Decker: Shelton, 2009.
4. Bresalier, RS. Current Opinion in Gastroenterology. In: Large Intestine. 24, No. 1. Lippincott, Williams and Wilkins, 2008.
5. Bresalier, RS. Ed(s) Bresalier, RS. Current Opinion in Gastroenterology. In: Large Intestine. Vol. 23, No. 1. Lippincott, Williams and Wilkins, 2007.
6. Bresalier, RS. Ed(s) Bresalier, RS. Current Treatment Options in Gastroenterology. In: Colon and Anorectum. Vol. 10, No 3. Current Science: Philadelphia, 2007.

Grant & Contract Support

Title: Non-Invasive mRNA Based Biomarkers for Detection of Colorectal Neoplasia
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 4/1/2011 - 3/31/2014
 
Title: Galectin-3 Polymorphisms in Colorectal Cancer Biology
Funding Source: Department of Defense (DOD)
Role: Co-Principal Investigator
Duration: 4/1/2011 - 3/31/2014
 
Title: Early Detection Research Network. Great Lakes-New England Clinical and Epidemiology Center
Funding Source: National Cancer Institute
Role: Robert S. Bresalier, Co-Investigator, Center Principal Investigator
Principal Investigator: Dean Brenner
Duration: 10/1/2010 - 7/31/2015
 
Title: A Circulating Ligand for Galectin-3 in the Serum of Individuals with Colorectal Neoplasia: Population Differences in Caucatians and Hispanics in Puerto Rico and Houston
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2013
 
Title: Early Detection Research Network-Great Lakes-New England Clinical, Epidemiology and Validation Center
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 8/1/2010 - 7/31/2015
 
Title: Non-Invasive Detection of Colorectal Neoplasia using Intestinal Gene Expression Profiles
Funding Source: TAMU/NIH
Role: Investigator
Duration: 7/1/2010 - 6/30/2015
 
Title: Non-Invasive Detection of Colorectal Neoplasia Using Intestinal Gene Expression Profiles.
Funding Source: NIH
Role: Principal Investigator
Duration: 3/2010 - 2/2015
 
Title: Mucin glycoproteins in colorectal cancer metastasis
Funding Source: National Institutes of Health/National Cancer Institute
Role: Principal Investigator
Duration: 9/1/2006 - 8/1/2012
 
Title: Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett’s Esophagus
Funding Source: This multi-center study has been funded by NCI under a Phase I/Phase II Trials of Chemoprevention Contract
Role: Robert S. Bresalier, Co-Investigator, Center Principal Investigator
Principal Investigator: Andrew Joe
Duration: 2006 - 2013
 
Title: 15-LOX-1 and Clinical Chemoprevention of Colon Tumors
Funding Source: National Cancer Institute, National Institutes of Health
Role: Robert S. Bresalier, Co-Investigator
Principal Investigator: Shureiqi
Duration: 4/1/2005 - 3/30/2008
 
Title: Calcium/Vitamin D, Biomarkers and Colon Polyp Prevention
Funding Source: National Cancer Institute, National Institutes of Health
Role: Robert S. Bresalier, Co-Investigator, Center Principal Investigator
Principal Investigator: Robert Bostic,
Duration: 1/1/2005 - 6/30/2010
 
Title: Colorectal Chemoprevention with Calcium and Vitamin D
Funding Source: National Cancer Institute-National Institutes of Health
Role: Robert S. Bresalier, Co-Investigator, Center Principal Investigator
Principal Investigator: Baron
Duration: 1/1/2004 - 8/31/2013

Last updated: 8/26/2013